Meeting reportRubella vaccines: WHO position paper—Recommendations
References (5)
- et al.
Collaborative Group for the Study of Yellow Fever Vaccines, Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella
Vaccine
(2011) Rubella vaccines: WHO position paper
Wkly Epidemiol Rec
(2011)
Cited by (30)
Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial
2022, The Lancet Global HealthCitation Excerpt :Seroconversion was defined as a four-fold rise or more in antibody titre from day 0 to day 28 and from day 0 to day 730–1035 after vaccination. Seroprotection was defined in accordance with the WHO standard reference values of GMT of 120 mIU/mL for measles or higher and 10 IU/mL or higher for rubella.22,23 Study results were analysed using SAS software, version 9.4.
Adverse pregnancy outcomes among pregnant women with acute Rubella infections in Mwanza city, Tanzania
2019, International Journal of Infectious DiseasesCitation Excerpt :Additionally, the coverage of Measles first dose vaccine was around 80% with some regions reported below 80% (Semali, 2010). It should be noted that the main prerequisite, prior to the introduction of the Rubella vaccine, is to achieve a first dose Measles vaccine coverage of not lower than 80% (Publication, 2011). Introducing the Rubella vaccine when the Measles vaccine coverage is low may result into a shift of average age exposure due to the presence of non-immune individuals and eventually increase the prevalence of CRS.
Rubella Virus
2018, Principles and Practice of Pediatric Infectious DiseasesSociodemographic and economic characteristics of susceptibility to rubella among women preparing for pregnancy in rural China
2017, International Journal of Infectious DiseasesRubella
2015, The LancetCitation Excerpt :The plan includes a five-pronged strategy to: achieve and maintain high levels of population immunity with 95% or higher vaccination coverage with two doses of measles-containing and rubella-containing vaccines; monitor disease with effective surveillance and assess programmatic efforts; develop outbreak preparedness and respond rapidly to outbreaks; communicate and engage with the public to build confidence in and demand for immunisation; and undertake the research and development needed to support cost-effective operations and improve vaccination and diagnostic methods. In 2011, WHO updated its guidance on rubella-containing vaccine use with a clear recommendation that countries that have not yet introduced rubella-containing vaccines should take the opportunity of accelerated measles control and elimination activities to include rubella-containing vaccines in their immunisation programmes.47 Because all countries have elimination targets, their measles vaccine delivery strategies provide a platform to advance rubella and congenital rubella syndrome elimination through the use of combined vaccines (eg, measles–rubella vaccine [MR] or MMR).
Rubella susceptibility in pregnant women and results of a postpartum immunization strategy in Catalonia, Spain
2015, VaccineCitation Excerpt :Post-delivery vaccination strategies should include MMR vaccination in women susceptible to these diseases. In susceptible pregnant women, immunization with this live attenuated vaccine should be administrated during the postpartum period [2,9,10]. In Spain, rubella is a notifiable disease and is monitored through the Spanish Surveillance System [11].